MYC-Inhibitor
Showing 1 - 25 of 7,459
Metastatic Pancreatic Cancer Trial in Spain (OMO-103, Nab-Paclitaxel, Gemcitabine)
Recruiting
- Metastatic Pancreatic Cancer
- OMO-103
- +2 more
-
LĀ“Hospitalet de Llobregat, Barcelona, Spain
- +3 more
Sep 22, 2023
Advanced Solid Tumors, NSCLC, Triple-negative Breast Cancer Trial in Barcelona, Madrid (OMO-103)
Active, not recruiting
- Advanced Solid Tumors
- +3 more
- OMO-103
-
Barcelona, Spain
- +2 more
Sep 27, 2022
Hepatocellular Carcinoma, Solid Tumor, Hepatocellular Carcinoma Non-resectable Trial in San Antonio (OTX-2002, Tyrosine kinase
Not yet recruiting
- Hepatocellular Carcinoma
- +6 more
- OTX-2002
- +3 more
-
San Antonio, TexasNext Oncology
Aug 9, 2022
Recurrent ALK Positive Large B-Cell Lymphoma, Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between
Not yet recruiting
- Recurrent ALK Positive Large B-Cell Lymphoma
- +28 more
- Biospecimen Collection
- +5 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Aug 17, 2022
DLBCL, DLBCL Activated B-Cell Type, DLBCL Germinal Center B-Cell Type Trial in Chicago (Cyclophosphamide, Doxorubicin
Active, not recruiting
- Diffuse Large B-Cell Lymphoma
- +6 more
- Cyclophosphamide
- +5 more
-
Chicago, IllinoisNorthwestern University
Apr 30, 2021
CNS Tumor, Solid Tumor Trial in Worldwide (Nivolumab and Entinostat)
Recruiting
- CNS Tumor
- Solid Tumor
- Nivolumab and Entinostat
-
Randwick, New South Wales, Australia
- +13 more
Nov 8, 2022
Diffuse Large B-cell Lymphoma(DLBCL) Trial in Shanghai (Zanubrutinib + R-CHOP)
Recruiting
- Diffuse Large B-cell Lymphoma(DLBCL)
- Zanubrutinib + R-CHOP
-
Shanghai, ChinaFudan University Shanghai Cancer Center
Feb 10, 2022
Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma, Recurrent Endometrial Endometrioid
Not yet recruiting
- Recurrent Endometrial Carcinoma
- +8 more
- BET Bromodomain Inhibitor ZEN-3694
- +7 more
- (no location specified)
Jul 15, 2023
Breast Cancer Trial in Marseille (M1774, Fulvestrant injection)
Not yet recruiting
- Breast Cancer
- M1774
- Fulvestrant injection
-
Marseille, FranceInstitut Paoli Calmettes
Aug 9, 2023
Recurrent Ovarian High Grade Serous Adenocarcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma Trial in United States
Suspended
- Recurrent Ovarian High Grade Serous Adenocarcinoma
- Recurrent Platinum-Resistant Ovarian Carcinoma
-
Phoenix, Arizona
- +8 more
Jul 26, 2022
Adenosquamous Carcinoma of the Pancreas Trial run by the NCI (Minnelide)
Recruiting
- Adenosquamous Carcinoma of the Pancreas
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jul 7, 2022
Advanced Lymphoma, Advanced Malignant Solid Tumor, Advanced Pancreatic Carcinoma Trial in New Haven (BET Bromodomain Inhibitor
Recruiting
- Advanced Lymphoma
- +13 more
- BET Bromodomain Inhibitor ZEN-3694
- +2 more
-
New Haven, ConnecticutYale University Cancer Center LAO
Jun 29, 2022
SCLC, Small Cell Cancer, Advanced Solid Tumor Trial run by the NCI (Lurbinectedin, Berzosertib)
Recruiting
- SCLC
- +3 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 20, 2023
Small-cell Lung Cancer, Small Cell Lung Carcinoma Trial in Pittsburgh (Onvansertib)
Recruiting
- Small-cell Lung Cancer
- Small Cell Lung Carcinoma
-
Pittsburgh, PennsylvaniaUPMC Hillman Cancer Center
Jul 29, 2022
Lymphoma, Non-Hodgkin Lymphoma, NHL Trial run by the National Cancer Institute (NCI) (Vysis LSI MYC Break Apart Rearrangement
Recruiting
- Lymphoma
- +4 more
- Vysis LSI MYC Break Apart Rearrangement Probe Kit
- +3 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Feb 2, 2023
Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Tumor, Advanced Ovarian Carcinoma Trial in Bethesda, Boston (Biopsy,
Recruiting
- Advanced Fallopian Tube Carcinoma
- +21 more
- Biopsy
- +2 more
-
Bethesda, Maryland
- +2 more
Jan 25, 2023
Metastatic Malignant Solid Tumor, Recurrent Malignant Solid Tumor, Recurrent Platinum-Resistant Ovarian Carcinoma Trial in
Recruiting
- Metastatic Malignant Solid Neoplasm
- +3 more
- BET Bromodomain Inhibitor ZEN-3694
- +2 more
-
Bethesda, Maryland
- +4 more
Aug 16, 2022
Refractory Malignant Solid Tumor Trial (PCNA Inhibitor AOH1996)
Recruiting
- Refractory Malignant Solid Neoplasm
- PCNA Inhibitor AOH1996
-
Scottsdale, Arizona
- +1 more
Sep 29, 2022
Phase 1, NSCLC, SCLC Trial in United States (Oral MRT-2359)
Recruiting
- NSCLC
- +6 more
- Oral MRT-2359
-
Scottsdale, Arizona
- +7 more
Dec 20, 2022
Diffuse Large B Cell Lymphoma Trial in Shanghai (zanubrutinib)
Recruiting
- Diffuse Large B Cell Lymphoma
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Mar 13, 2022
Solid Tumor, Childhood, Lymphoma, Brain Tumor, Pediatric Trial in Canada, United States (BMS-986158, BMS-986378)
Recruiting
- Solid Tumor, Childhood
- +2 more
-
Boston, Massachusetts
- +5 more
Dec 27, 2022